Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

3.615 +0.275 (+8.23%)
Streaming Delayed Price Updated: 11:05 AM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 170,045
Open 3.230
Bid (Size) 3.610 (4)
Ask (Size) 3.620 (7)
Prev. Close 3.340
Today's Range 3.230 - 3.615
52wk Range 1.575 - 7.270
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga

Performance

YTD
-7.5%
-7.5%
1 Month
+20.5%
+20.5%
3 Month
-4.4%
-4.4%
6 Month
+18.1%
+18.1%
1 Year
+33.4%
+33.4%

More News

Read More
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
4 Analysts Assess Amylyx Pharma: What You Need To Know
Via Benzinga
Earnings Scheduled For March 4, 2025
Via Benzinga
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In November
Via Benzinga
Exposures Fossil Fuels
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
Via Benzinga
This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week
Via The Motley Fool
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are Buying
Via Benzinga
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and Neurodegeneration
From Amylyx Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Amylyx Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Amylyx Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Amylyx Pharmaceuticals, Inc. - Common Stock trade on?
Amylyx Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock is AMLX on the Nasdaq Stock Market
What is the current price of Amylyx Pharmaceuticals, Inc. - Common Stock?
The current price of Amylyx Pharmaceuticals, Inc. - Common Stock is 3.615
When was Amylyx Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Amylyx Pharmaceuticals, Inc. - Common Stock was at 04/02/25 11:05 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS